retatrutide glp 3 GLP-3 R 30mg GLP-3 R (GLP-1 | GIP

Because Medicare patients often face overlapping risks such as chronic kidney disease and cardiovascular complications, multi-indication agents such as the SGLT2s remain an important complementary option alongside GLP1s

Compounded sublingual drops are liquid formulations of semaglutide or tirzepatide prepared by compounding pharmacies

Opportunities for Manufacturers in UMIC: How Price Reduction Can Drive Adoption Source: UMIC countries as per World Bank definition In price-sensitive markets, affordability not awareness is the dominant adoption gate for GLP-1 obesity therapies

Retatrutide, an investigational triple GIP/GLP-1/glucagon receptor agonist developed by Eli Lilly, demonstrated unprecedented weight loss in Phase 2 trials but has not yet completed Phase 3 development